Interruptions of high-dose radiation therapy decrease longterm survival of favorable patients with unresectable nonsmall cell carcinoma of the lung: analysis of 1244 cases from 3 radiation therapy oncology group (RTOG) trials
James D. Cox, Thomas F. Pajak, Sucha O. Asbell et al. · International Journal of Radiation Oncology*Biology*Physics · 1993
Cited by 227 works. doi:10.1016/0360-3016(93)90371-2
Authors
- James D. Cox
- Thomas F. Pajak
- Sucha O. Asbell
- Anthony Henryk Russell
- Roger W. Byhardt
- Bahman Emami
- Mack Roach
References
- Nonparametric Estimation from Incomplete Observations
- Nonparametric Estimation from Incomplete Observations
- Regression Models and Life-Tables
- Regression Models and Life-Tables
- Evaluation of survival data and two new rank order statistics arising in its consideration.
- A Randomized Trial of Induction Chemotherapy plus High-Dose Radiation versus Radiation Alone in Stage III Non-Small-Cell Lung Cancer
- Effects of Concomitant Cisplatin and Radiotherapy on Inoperable Non-Small-Cell Lung Cancer
- A re-evaluation of split-course technique for squamous cell carcinoma of the head and neck
- A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83-11.
- Twice-a-day radiation therapy for cancer of the head and neck